Exploring changes in treatment effects across design stages in adaptive trials

Pharmaceutical Statistics

Volumn 8, Issue 1, 2009, Pages 62-72

  Friede, Tim ^a   Henderson, Robin ^b  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Adaptive design; Calendar time effects; Change point; Clinical trial; Heterogeneity test

Indexed keywords

ADAPTIVE DESIGN; ARTICLE; CLINICAL PROTOCOL; CLINICAL STUDY; CONFOUNDING VARIABLE; CONTROLLED STUDY; DATA ANALYSIS; EXPLORATORY RESEARCH; HUMAN; INFORMATION RETRIEVAL; METHODOLOGY; OUTCOMES RESEARCH; POWER OF A TEST; RESPONSE TIME; SAMPLE SIZE; STATISTICAL MODEL; SYSTEMATIC ERROR; TREATMENT RESPONSE; CLINICAL TRIAL; COMPUTER SIMULATION; META ANALYSIS; PRACTICE GUIDELINE; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; GUIDELINES AS TOPIC; HUMANS; META-ANALYSIS AS TOPIC; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 65649112030     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.332     Document Type: Article

References (31)

1. Bauer P, Köhne K. Evaluation of experiments with adaptive interim analyses. Biometrics 1994; 50:1029-1041.
2. Kuehn BM. Industry, FDA warm to 'adaptive' trials. Journal of the American Medical Association 2006; 296:1955-1957.
3. FDA. Critical path opportunities list 2006. http://www.fda.gov/oc/ initiatives/criticalpath/.
4. Brannath W, Posch M, Bauer P. Recursive combination tests. Journal of the American Statistical Association 2002; 97:236-244.
5. Schäfer H, Timmesfeld N, Müller H-H. An overview of statistical approaches for adaptive designs and design modifications. Biometrical Journal 2006; 48:507-520.
6. Bauer P, KieserM. Combining different phases in the development of medical treatments within a single trial. Statistics in Medicine 1999; 18:1833-1848.
7. Bretz F, Schmidli H, König F, Racine A, Maurer W. Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: general concepts. Biometrical Journal 2006; 48:623-634.
8. Maca J, Bhattacharya S, Dragalin V, Gallo P, Krams M. Adaptive seamless phase II/III designs: background, operational aspects, and examples. Drug Information Journal 2006; 40:463-473.
9. Schmidli H, Bretz F, Racine A, Maurer W. Confirmatory seamless phase II/ III clinical trials with hypotheses selection at interim: applications and practical considerations. Biometrical Journal 2006; 48:635-643.
10. Stallard N, Todd S. Sequential designs for phase III clinical trials incorporating treatment selection. Statistics in Medicine 2003; 22:689-703.
11. Phillips AJ, Keene ON. Adaptive designs for pivotal trials: discussion points from the PSI Adaptive Design Expert Group. Pharmaceutical Statistics 2006; 5:61-66.
12. Gallo P, Chuang-Stein C, Dragalin V, Gaydos B, Krams M, Pinheiro J. Adaptive designs in clinical drug development - an executive summary of the PhRMA Working Group. Journal of Biopharmaceutical Statistics 2006; 16:275-283.
13. Committee for Medicinal Products for Human Use. Reflection paper on methodological issues in confirmatory clinical trials with flexible design and analysis plan. London, 18 October 2007. Doc. Ref. CHMP/EWP/ 2459/02, 2006.
14. Higgins JPT, Green S (ed.). Cochrane handbook for systematic reviews of interventions 4.2.6 [updated September 2006]. The Cochrane Collaboration; http://www.cochrane.org/resources/handbook/hbook.htm (accessed 6.06.2007).
15. Whitehead A. Meta-analysis of controlled clinical trials. Wiley: Chichester, 2002.
16. Gallo P. Confidentiality and trial integrity issues for adaptive designs. Drug Information Journal 2006; 40.
17. Altman DG, Royston JP. The hidden effect of time. Statistics in Medicine 1988; 7:629-637.
18. Gallo P, Maurer W. Challanges in implementing adaptive designs: comments on the viewpoints expressed by regulatory statisticians. Biometrical Journal 2006; 48:591-597.
19. Liu KS, Snavely DB, Ball WA, Lines CR, Reines SA, Potter WZ. Is bigger better for depression trials? Journal of Psychiatric Research, 2007; in press.
20. Posch M, Bauer P. Interim analysis and sample size reassessment. Biometrics 2000; 56:1170-1176.
21. Friede T, Kieser M. A comparison of methods for adaptive sample size adjustment. Statistics in Medicine 2001; 20:3861-3873.
22. Heuer C, Abel U. The analysis of intervention effects using observational data bases. In Nonrandomized comparative clinical studies, Abel U, Koch A (eds). Symposium Publishing: Düsseldorf, 1998; 101-107.
23. Friede T, Henderson R. Intervention effects in observational studies with an application in total hip replacements. Statistics in Medicine 2003; 22:3725-3737.
24. Friede T, Henderson R, Kao CF. A note on testing for intervention effects on binary responses. Methods of Information in Medicine 2006; 45:435-440.
25. Davies RB. Hypothesis testing when a nuisance parameter is present only under the alternative. Biometrika 1987; 74:33-43.
26. Andrews DA, Ploberger W. Optimal tests when a nuisance parameter is present only under the alternative. Econometrica 1994; 62:1383-1414.
27. Hansen BE. Approximate asymptotic p values for structural-change tests. Journal of Business & Economic Statistics 1997; 15:60-67.
28. Senn S. Cross-over trials in clinical research (2nd edn). Wiley: Chichester, 2002.
29. Faldum A. Homogeneity of stages in adaptive designs. Presentation at the Fifth International Conference on Multiple Comparions Procedures (MCP), Vienna, 8-11 July 2007.
30. Gallo P. Statistical assessment of change within adaptive trials. Presentation at the 43rd Annual Meeting of the Drug Information Association, Atlanta, June 2007.
31. Liu Q, Pledger GW. Phase II and III combination designs to accelerate drug development. Journal of the American Statistical Association 2005; 100:493-502.